Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment

This article was originally published in The Tan Sheet

Executive Summary

Sales exceeding $150 million in two weeks on retail shelves for OTC weight-loss drug alli figure prominently in GlaxoSmithKline's commitment to its consumer health care products division, senior executives say

You may also be interested in...



FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones

FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.

FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones

FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.

GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales

GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel